SCHEMBL95227

SCHEMBL95227

[CH2]c1ccc(C(=O)N(C)CC(=O)Nc2ccc(C)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
ALDH1A1 P00352 1/20 0.61
TDP1 Q9NUW8 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
PSMD14 O00487 1/20 0.57
MMP2 P08253 1/20 0.57
DNMT1 P26358 1/20 0.57
CASP6 P55212 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
GAA P10253 1/20 0.51
MEN1 O00255 2/20 0.50
POLB P06746 1/20 0.50
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23417114 0.77 KMT2A (0.47) KMT2AALDH1A1TDP1L3MBTL1PSMD14
SCHEMBL12231007 0.76 TDP1 (0.62) KMT2AALDH1A1TDP1L3MBTL1PSMD14
SCHEMBL764662 0.75 POLB (0.68) KMT2AALDH1A1TDP1L3MBTL1GAA
SCHEMBL13607093 0.75 POLB (0.58) KMT2AALDH1A1L3MBTL1CASP6GAA
SCHEMBL96971 0.75 MMP13 (0.58) KMT2AMEN1MAPT
SCHEMBL95796 0.74 POLB (0.40) KMT2AALDH1A1TDP1L3MBTL1MEN1
SCHEMBL95844 0.74 RAB9A (0.81) KMT2AALDH1A1TDP1L3MBTL1GAA
SCHEMBL20225947 0.73 L3MBTL1 (1.00) KMT2AALDH1A1TDP1L3MBTL1PSMD14
SCHEMBL4008336 0.72 HPGD (0.59) KMT2AALDH1A1POLBLMNAMAPT
SCHEMBL20851771 0.72 POLB (0.74) KMT2AALDH1A1TDP1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KMT2A 1059/4885ALDH1A1 2948/4885TDP1 3588/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KMT2A 2732/4885ALDH1A1 2458/4885TDP1 4079/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KMT2A 2732/4885ALDH1A1 2458/4885TDP1 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.